About US
Contact us
-
Gilead's hep C drugs make it king of the hill in U.S. drug salesThe U.S. drug market is the largest in the world and just about every drugmaker wants the biggest piece of it that it can get. For 2014 that honor goes to biotech Gilead Sciences ($GILD), whose hep C2015/4/16
-
Record new drug sales give a mega-boost to U.S. drug spendingGiven the flood of numbers onhepatitis Ctreatment costs, it's no surprise that U.S. drug spending took a leap last year. Given the news on specialty drug prices, it's also no surprise that the biggest2015/4/15
-
Onglyza's label should flag heart failure risks, FDA panel saysAstraZeneca ($AZN) escaped the worst with anFDApanel vote on Onglyza. The agency's expert advisers almost unanimously backed the drug's cardiovascular safety. But the panel also recommended that the d2015/4/15
-
2015’ PHEXTOUR Excipients Application Technology (Asia) Tour Seminar--Jakarta Station2015’PHEXTOURExcipients Application Technology (Asia) Tour Seminar--Jakarta Station,was successfully held at Hotel Ciputra on 7 April,2015. The seminar was organized by Phexcom and MegaSetia,co-org2015/4/14
-
Actavis chairman joins Zoetis board under deal with activist investor AckmanPfizer ($PFE) spinoff Zoetis ($ZTS), the animal health company, added a second director to its board under a deal it reached earlier this year with activist investorBill Ackmanand his firm Pershing Sq2015/4/14
-
Valeant CEO's 2014 pay pales in comparison to new EVP's $50M-plusValeant Pharmaceuticals ($VRX) CEOJ. Michael Pearsontook down more than $10 million last year, including a whopping $8 million in incentive pay. But the real surprises in the company's 2015 proxy stat2015/4/14
-
Vertex's Kalydeco combo could run payers $10M-plus per life, PBM figuresSky-high drug prices have been causing their fair share of consternation among payers lately, and industry watchers have suspected for a while now that Vertex ($VRTX) will stir the pot when its new cy2015/4/13
-
AstraZeneca's Onglyza 'mortality' risks noted by FDA reviewersFor several years, theFDAhas been supercautious about the heart risks of diabetes treatments. Now, FDA staff reviewers have raised serious concerns about the safety of AstraZeneca's ($AZN) Onglyza ahe2015/4/13
-
Head of Indian pricing authority pushed out after price hikesThe head ofIndia's National Pharmaceutical Pricing Authority was removed from the job just a week after his agency allowed the prices of 509 essential drugs to increase by 3.8%. But Chairman Injeta Sr2015/4/10
-
Natco brings its scrappy style to U.S. with Copaxone, Revlimid knockoffsGenerics playerNatco Pharmahas already made plenty of waves in the Indian pharma market with cheaper versions of blockbuster meds, playing by a patent challenge strategy that's ignited the ire of more2015/4/10